Protocol Ledger

Biopharma Industry · Consolidated Sponsor Hub

Novo Nordisk: Clinical Trials & FDA Approval Profile

Novo Nordisk (Bagsvaerd, DK / Plainsboro, NJ) sponsors 176 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 60 active protocols (31 recruiting now), 104 completed protocols, and 20 all-time original FDA Drugs@FDA NDA and BLA approvals.

Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)6.8%
Median Closed Enrollment vs National (145 pts)300 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Novo Nordisk
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)176
Active Pipeline (Recruiting Now)60 (31)
Completed vs Stopped Early104 / 12 (6.8%)
Median Closed Actual Enrollment300 participants
Physical Hospital Site Disclosure95.3% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals20 (5 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Novo Nordisk
Hospital Research SiteLocationShared Protocols
UT Southwestern Simmons Cancer CenterDallas, TX40
Diablo Clinical Research IncWalnut Creek, CA28
Hospital Vall d' HebronBarcelona27

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Novo Nordisk
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT07207811CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart FailurPhase IIIRECRUITING
NCT06612268A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell DiseasePhase IIIRECRUITING
NCT07301034A Research Study to Look at the Effect of Ziltivekimab on Plaque in the Blood Vessels of the Heart, Compared to Placebo, in People With a HePhase IIIRECRUITING
NCT06979362A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure WPhase IIRECRUITING
NCT07770841Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body WeightPhase IIIRECRUITING

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Novo Nordisk across sibling Meru public-data platforms.

Explore interactive annual charts and M&A subsidiary rollups in the Novo Nordisk Interactive Dossier, benchmark peers in Endocrinology, Obesity, and Metabolic, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI